logo

For the Inventor, By the Inventor

Como, Italy

Claudio Giuliano

This inventor holds 21 USPTO granted patents and 4 published patent applications and 7 EPO patents, primarily in Asymmetric Ureas. Top assignees: Helsinn Healthcare Sa, Anacardio Ab, Other. Active years: 2013-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Claudio Giuliano. Retrieved from https://idiyas.com/inventor/claudio-giuliano

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 21 

% Patents Active = 90.5

 

Average Co-Inventor Count = 5.4

ph-index = 3

Forward Citations = 31(Granted Patents)


Company Filing History:

goldMedal20 out of 70 
 
Helsinn Healthcare Sa
 patents
silverMedal2 out of 2 
 
Anacardio Ab
 patents
bronzeMedal1 out of 834,513 
Other
 patents
where one patent can have more than one assignee

Years Active: 2013-2026

Loading Chart...
Loading Chart...
Areas of Expertise:
Inotropic Agents
Ghrelin Agonist
Piperidine Derivatives
Emesis Treatment
Chloromethyl Dialkylphosphates
Fumarate Salts
Neurokinin Receptor Modulator
Asymmetric Ureas
Pharmaceutical Composition
Substituted Piperaziniums
Medicinal Chemistry
Anti-Emetic Effect
21 patents (USPTO):Explore Patents
1. 12648941 - Piperidine urea derivatives for use as inotropic agents (2026-06-09),
2. 12569476 - Piperidine urea derivatives for use as inotropic agents (2026-03-10),
3. 12440485 - Centrally-active ghrelin agonist and medical uses thereof (2025-10-14),
4. 12071421 - Process for the synthesis of substituted chloromethyl dialkylphosphates (2024-08-27),
5. 12005056 - Centrally-active ghrelin agonist and medical uses thereof (2024-06-11),
6. 11884646 - Fumarate salt of (R)-3-(1-(2,3-dichloro-4-(pyrazin-2-yl)phenyl)-2,2,2-trifluoroethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea, methods of preparation, and uses thereof (2024-01-30),
7. 11312698 - Fosnetupitant chloride hydrochloride having improved stability (2022-04-26),
8. 11299472 - Fumarate salt of (R)-3-(1-(2,3-dichloro-4-(pyrazin-2-yl)phenyl)-2,2,2- trifluoroethyl)-1-methyl-1-(1-methylpiperidin-4-yl) urea, methods of preparation, and uses thereof (2022-04-12),
9. 10717721 - Substituted piperaziniums for the treatment of emesis (2020-07-21),
10. 10577384 - Substituted asymmetric ureas as modulators of ghrelin receptor activity (2020-03-03),
11. 10501479 - Benzenesulfonyl-asymmetric ureas and medical uses thereof (2019-12-10),
12. 10407390 - Asymmetric ureas and medical uses thereof (2019-09-10),
13. 10208073 - Solution comprising the chloride hydrochloride salt of 4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-IUM-(fosnetupitant) and palonosetron hydrochloride in combination with dexamethasone as a neurokinin receptor modulator (2019-02-19),
14. 9926337 - Substituted asymmetric ureas as modulators of ghrelin receptor activity (2018-03-27),
15. 9908907 - Substituted piperaziniums for the treatment of emesis (2018-03-06),

Title: Innovations and Patents of Claudio Giuliano

Introduction

Claudio Giuliano, an accomplished inventor based in Como, Italy, has made significant strides in the field of pharmaceuticals with a notable portfolio of 18 patents. His innovations primarily focus on advancements in drug synthesis and the treatment of various medical conditions.

Latest Patents

Among Claudio's latest patents is a process for the synthesis of substituted chloromethyl dialkylphosphates. This patent discloses compounds, including phosphate and N-oxide prodrugs of the NK1 antagonist netupitant. These compounds are particularly useful in preventing and treating emesis induced by chemotherapy. The methods outlined for manufacturing di-tert-butyl (chloromethyl) phosphate involve a series of chemical reactions that transform dialkylphosphate salts into effective prodrugs.

Another remarkable patent by Claudio is the development of a centrally-active ghrelin agonist. This compound, 3-(1-(2,3-dichloro-4-methoxyphenyl) ethyl)-1-methyl-1-(1,3,3-trimethylpiperidin-4-yl) urea monohydrochloride salt, demonstrates a high ability to cross the blood-brain barrier. It shows considerable efficacy in treating neurotoxic damage and conditions that necessitate a reduction in heart rate. This compound exhibits pharmacological activity at low to moderate doses, indicating a promising therapeutic index.

Career Highlights

Claudio has garnered extensive experience in the pharmaceutical industry, having contributed to innovative projects at Helsinn Healthcare Sa. His work reflects a deep commitment to improving therapeutic options available for patients, particularly in areas that address pressing health needs.

Collaborations

Throughout his career, Claudio has worked alongside esteemed colleagues such as Claudio Pietra and Silvina Garcia Rubio. These collaborations have fostered an environment of shared knowledge and innovation, leading to groundbreaking advancements in their respective fields.

Conclusion

Claudio Giuliano stands out as a significant figure in the landscape of pharmaceutical innovations. With a portfolio of numerous patents and impactful collaborations, his work continues to influence the development of new treatments and enhance the quality of healthcare.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…